

LIST OF REFERENCES CITED BY APPLICANT  
(Use several sheets if necessary)

ATTY DOCKET NO.

10271-048-999

APPLICATION NO

09/996,265

APPLICANT

Young et al.

FILING DATE

November 28, 2001

GROUP

1648

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
SBC	DL	5,939,068	8/17/99	Brams et al.	—	—	
SBC	DM	5,811,524	9/22/98	Brams et al.	—	—	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
SBC	DN	WO 96/05229	2/22/96	PCT	—	—		

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

SBC	DO	Hacking et al., 2002, "Respiratory syncytial virus - viral biology and the host response," J. Infection 45:18-24
	DP	Heard et al., 1999, "Two neutralizing human RSV antibodies: cloning, expression, and characterization," Mol. Med. 5:35-45
	<del>DQ</del>	<del>Landry et al., "Evaluation of reconstituted topilized palivizumab given intravenously at 15 and 30 mg/kg," Poster Session, Tuesday, Infect. Dis. 166A: 969</del>
	DR	Saez-Llorens et al., 1997, "Phase I/II open label multi dose escalation trial of a humanized respiratory syncytial virus (RSV) monoclonal antibody (Medi-493) administered intramuscularly (IM) in high risk children," Abstracts in Non HIV virology, ICAAC Toronto
	DS	Subramanian et al., 1997, "Randomized double blind placebo controlled dose escalation trial of a humanized respiratory syncytial virus monoclonal antibody in high risk infants," Poster session infect. dis. 130A:768
	DT	Sorbera et al., 1998, "Palivizumab," Drugs of the Future 23:970-976
↓	DU	Sorbera et al., 1998, "Palivizumab," Drugs Data Report 20:702-703

EXAMINER

Stacy B. Chen

DATE CONSIDERED

February 26, 2004

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

BEST AVAILABLE COPY

NY2: 1487649.1